title: Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.
authors.affiliation: Internal Medicine Department, French National Center for Rare Systemic Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.|Paris VI University, UPMC, Sorbonne Universités, Paris, France.
authors.forename: Fleur
authors.initials: F
authors.lastname: Cohen Aubart
authors.affiliation: EA4340, Pathology Department, Ambroise Paré Hospital, Versailles University, AP-HP, Boulogne, France.
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Emile
authors.affiliation: Nuclear Medicine Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Maksud
authors.affiliation: Neuroradiology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
authors.forename: Damien
authors.initials: D
authors.lastname: Galanaud
authors.affiliation: Vascular Imaging Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Cluzel
authors.affiliation: Pharmacy Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
authors.forename: Neila
authors.initials: N
authors.lastname: Benameur
authors.affiliation: Internal Medicine Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Aumaitre
authors.affiliation: Internal Medicine Department, French National Center for Rare Systemic Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.|Paris VI University, UPMC, Sorbonne Universités, Paris, France.
authors.forename: Zahir
authors.initials: Z
authors.lastname: Amoura
authors.affiliation: Internal Medicine Department, French National Center for Rare Systemic Diseases, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.|Paris VI University, UPMC, Sorbonne Universités, Paris, France.
authors.forename: Julien
authors.initials: J
authors.lastname: Haroche
mesh_terms: D000328:Adult; D000368:Aged; D001384:Azetidines / Q000494:pharmacology / Q000627:therapeutic use*; D031249:Erdheim-Chester Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D019788:Fluorodeoxyglucose F18; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D001384:Azetidines; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D019788:Fluorodeoxyglucose F18; D048493:Proto-Oncogene Proteins B-raf; C574276:cobimetinib
keywords: Erdheim-Chester disease; MAP2K1 mutation; cobimetinib